对于全身应用氨甲喋吟(MTX)最初敏感而以后发生耐药的白血病病人,鞘内注射MTX对于中枢神经系统(CNS)白血病可仍然有效。有人曾随机选择最近诊断为急性白血病的47名儿童,在诊断后的24小时之内鞘内注射MTX0.9毫克/公斤/次,对照组不作鞘内注射。结果一次鞘内注射组不能防止或减少CNS浸润的发生率,但可延迟CNS白血病发生。有人在用鞘内注射MTX治疗CNS白血病 Intrathecal injection of MTX may still be effective for central nervous system (CNS) leukemia in patients with leukemia who are initially susceptible to systemic exposure to methotrexate (MTX) and subsequently develop resistance. Forty-seven children who had recently been diagnosed as having acute leukemia were randomized to receive intrathecal MTX (0.9 mg / kg / d) within 24 hours of diagnosis and no intrathecal injection of control group. Results One intrathecal injection did not prevent or reduce the incidence of CNS infiltration but delayed CNS leukemia. Some people are using intrathecal MTX treatment of CNS leukemia